DOI: 10.36347/sjams.2023.v11i01.036

Pages: 236-241

Introduction: In women of reproductive age, PCOS is a prevalent endocrine illness characterized by irregular menstrual cycles, many tiny ovarian cysts, and high levels of androgens. Insulin resistance is one of the leading causes of PCOS. Insulin sensitizers can help increase cells' sensitivity to insulin, allowing them to respond more effectively to insulin and transport glucose into the cells. Aim of the Study: The study's objective was to evaluate how PCOS women used insulin sensitizer as an ovulation inducer. Methods: This was a prospective, observational, cross-sectional research at the Manikganj 250 Bedded Sadar hospital, Dhaka, Bangladesh. The study duration was 1 year, from January 2022 to December 2022. During this period, 100 patients with PCOS were selected following the inclusion and exclusion criteria for their participation in this study. Result: The study population consisted of young individuals with a mean age of 24.91 years, a moderate-to-high body mass index of 26.79 kg/m2, a moderate waist-to-hip ratio of 0.82, high fasting insulin level of 21.00 µIU/mL, high insulin area under the curve (AUC) of 308.32, moderate luteinizing hormone (LH) level of 10.90 mIU/mL, moderate follicle-stimulating hormone (FSH) level of 5.43 mIU/mL, a high LH:FSH ratio of 2.02, and moderate free testosterone level of 2.72 pg/mL. After 4 months of treatment with metformin, 80% of the participants had ovulation induction, with 33% having at least one ovulation, 25% having 2 ovulations, and 6% having 4 ovulations. After continuous treatment with metformin for 16 weeks, the study population had a mean body mass index of 26.22 kg/m2, a moderate waist-to-hip ratio of 0.81, low fasting insulin level of 10.55 µIU/mL, low insulin area under the curve (AUC) of 183.00, low to moderate luteinizing hormone (LH) level of 5.32 mIU/mL, moderate follicle- stimulating hormone (FSH) level of 4.80 mIU/mL, a low LH:FSH ratio of 1.10, and low free testosterone level of 1.33 pg/mL. .....